Tugbainanc (Talk | contribs) |
Tugbainanc (Talk | contribs) |
||
Line 19: | Line 19: | ||
<h3>Composite Part 1:</h3> | <h3>Composite Part 1:</h3> | ||
− | < | + | <h4>FucO/ L-1,2-Propanediol Oxidoreductase</h4> |
<p> | <p> | ||
FucO is the gene that codes for L-1,2-propanediol oxidoreductase which is a NADH-linked, homodimer enzyme having the role | FucO is the gene that codes for L-1,2-propanediol oxidoreductase which is a NADH-linked, homodimer enzyme having the role | ||
Line 32: | Line 32: | ||
</p> | </p> | ||
− | < | + | <h5>Our circuit design for FucO gene</h5> |
<p> | <p> | ||
Our circuit consists of prefix, a strong promoter (J23100), RBS (B0034), FucO as protein coding region, double terminator (B0015) | Our circuit consists of prefix, a strong promoter (J23100), RBS (B0034), FucO as protein coding region, double terminator (B0015) | ||
Line 69: | Line 69: | ||
<p> | <p> | ||
We’ve inserted the FucO composite part to pSB1C3 and pSB1A3 backbones. Then, we’ve transformed the construct for submission, BBa_K2571003, | We’ve inserted the FucO composite part to pSB1C3 and pSB1A3 backbones. Then, we’ve transformed the construct for submission, BBa_K2571003, | ||
− | (in pSB1C3) to | + | (in pSB1C3) to Dh4 alpha; and the other construct, for our biochemical assay, (in pSB1A3) to KO11. As we isolated the plasmids, we’ve done |
PCR with FucO left and VR primers to test orientation of our parts to the backbone. We expected a band of 754 bp between the FucO left and | PCR with FucO left and VR primers to test orientation of our parts to the backbone. We expected a band of 754 bp between the FucO left and | ||
VR primers and the PCR results confirmed our expectations and showed that our parts were correctly inserted and transformed. | VR primers and the PCR results confirmed our expectations and showed that our parts were correctly inserted and transformed. | ||
Line 75: | Line 75: | ||
<h3>Composite 2:</h3> | <h3>Composite 2:</h3> | ||
− | < | + | <h4>GSH:Bifunctional gamma-glutamate-cysteine ligase/glutathione synthetase</h4> |
<p> | <p> | ||
Line 99: | Line 99: | ||
</p> | </p> | ||
− | < | + | <h5>Our circuit design for GSH gene</h5> |
<p> | <p> | ||
Line 112: | Line 112: | ||
We’ve inserted the GSH composite part to pSB1C3 backbone. Then, we’ve transformed the construct for submission, | We’ve inserted the GSH composite part to pSB1C3 backbone. Then, we’ve transformed the construct for submission, | ||
<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2571005">BBa_K2571005</a>, (in pSB1C3) | <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2571005">BBa_K2571005</a>, (in pSB1C3) | ||
− | to | + | to Dh4 alpha and conducted colony PCR. We’ve made the PCR with GSH specific primers and expected to see a result of 225bp. By showing the |
band we expected, 225bp, PCR confirmation for our insertion proved right. | band we expected, 225bp, PCR confirmation for our insertion proved right. | ||
</p> | </p> | ||
<h3>Composite 3:</h3> | <h3>Composite 3:</h3> | ||
− | < | + | <h4>Dual Expression of FucO and GSH</h4> |
<p> | <p> | ||
Line 131: | Line 131: | ||
</p> | </p> | ||
− | < | + | <h4>Design Notes of Dual Expression of FucO and GSH</h4> |
<p> | <p> | ||
Line 166: | Line 166: | ||
Biotechnology for Biofuels, 3, 2. http://doi.org/10.1186/1754-6834-3-2 | Biotechnology for Biofuels, 3, 2. http://doi.org/10.1186/1754-6834-3-2 | ||
</div> | </div> | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
</div> | </div> | ||
</div> | </div> |
Revision as of 23:00, 27 September 2018